Navigation Links
Study reveals new mechanism that might promote cancer's growth and spread in the body
Date:7/10/2012

  • Researchers have discovered a previously unknown mechanism that promotes the growth and spread of cancer.
  • The mechanism involves a new role for small regulatory molecules called microRNA.
  • The findings suggest a new strategy for treating cancer and perhaps diseases of the immune system.

COLUMBUS, Ohio Tiny vesicles released by tumors cells are taken up by healthy immune cells, causing the immune cells to discharge chemicals that foster cancer-cell growth and spread, according to a study by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at Children's Hospital in Los Angeles.

The study uses lung cancer cells to show that the vesicles contain potent regulatory molecules called microRNA, and that the uptake of these molecules by immune cells alters their behavior. The process in humans involves a fundamental receptor of the immune system called Toll-like receptor 8 (TLR8).

The findings, published in the early edition of the Proceedings of the National Academy of Sciences, suggest a new strategy for treating cancer and diseases of the immune system, the researchers say, and a new role for microRNA in the body.

"This study reveals a new function of microRNA, which we show binds to a protein receptor," says principal investigator Dr. Carlo Croce, director of Ohio State's Human Cancer Genetics program and a member of the OSUCCC James Molecular Biology and Cancer Genetics program. "This tells us that some cancer-released microRNAs can bind and activate a receptor in a hormone-like fashion, and this has not been seen before."

MicroRNAs help control the type and amount of proteins that cells make, and they typically do this by binding with the messenger-RNA that encodes a protein.

"In this study we discovered a completely new mechanism used by cancer to grow and spread, therefore we can develop new drugs that fight tumors by entering this newly identified breach in cancer's fortress," says co-corresponding author and first author Dr. Muller Fabbri, assistant professor of Pediatrics and Molecular Biology and Immunology at the Keck School of Medicine of the University of Southern California.

"Equally exciting, we show that this mechanism involves a fundamental receptor of the immune system, TLR8, suggesting that the implications of this discovery may extend to other diseases such as autoimmune and inflammatory diseases," Fabbri says.

Key findings of the study include the following:

  • Lung tumor cells secrete microRNA-21 and microRNA-29a in vesicles called exosomes, and these exosomes are taken up by immune cells called macrophages located where tumor tissue abuts normal tissue.

  • In human macrophages, microRNA-29a and microRNA-21 bind with TLR8, causing the macrophages to secrete tumor-necrosis-factor alpha and interleukin-6, two cytokines that promote inflammation.

  • Increased levels of the two cytokines were associated with an increase in the number of tumors per lung in an animal model, while a drop in those levels led to a drop in the number per lung, suggesting that they also play a role in metastasis.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. New CDC study on racial disparities in infant mortality published in Journal of Womens Health
2. Police officer stress creates significant health risks, study finds
3. Nutrient Drink Might Boost Memory in Early Alzheimers: Study
4. Doctors overlook chemical illnesses, study finds
5. U.S. High Schools Lax in Preventing Dating Abuse: Study
6. Expensive, Drug-Emitting Stents May Be Overused: Study
7. Study suggests new screening method for sudden death in athletes
8. Einstein receives nearly $5 million to study how Ebola causes infection
9. UCLA study to determine if copper surfaces can reduce hospital-acquired infections
10. Uncircumcised Boys at Higher Risk for Infection: Study
11. Babies With Pets Not Dogged by Colds: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Crossing the ... last ten minutes of a woman’s life. “Crossing the Bar” is the creation of ... of three children. , Charlotte, who credits the inspiration of the book to ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... “Some Infallible ... of the Father. “Some Infallible Characteristics of Christ” is the creation of published author, ... of a Baptist Church for thirteen years, a preacher for over nineteen, a pastor ...
(Date:1/22/2017)... Raton, FL (PRWEB) , ... January 22, 2017 , ... ... to customers across the world, recently met with big-name retail buyers at the January ... scientific evidence of efficacy and uses the utmost safety standards in all of its ...
(Date:1/21/2017)... ... January 21, 2017 , ... Caronlab Australia, an Australian company known ... Trade Show in Hilton Head, SC, where it benefited from outstanding meetings with major ... its beauty and wellness products. At this trade show, the company had the chance ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at ... Oat is recognized globally as one of the healthiest cereals, XieQingkui, the founder of ... a move to sow the seed of good karma. Buddhism spirit featuring benevolence and ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... 23. Januar 2017  ResMed (NYSE: RMD ... 3B Medical ( Winter Haven, Florida ) ... über die Beilegung aller globalen Rechtsstreitigkeiten zwischen den Parteien ... ihrer bestehenden Produkte im Tausch gegen Lizenzgebühren an ... 3B leisten, um das in Florida ...
(Date:1/22/2017)... , Saudi Arabia , January 22, 2017 ... US and UAE discuss ... at the World Economic Forum   "The management and ... big data and powered by artificial intelligence and this trend is going to ... ,Hospital of the Future, at the concluding day of the 47 th ...
(Date:1/21/2017)... , Jan. 20, 2017  Today, during ... Conference, "PI3K Pathways in Immunology, Growth Disorders ... (NASDAQ: INFI ) presented preclinical ... candidate that selectively inhibits phosphoinositide-3-kinase-gamma (PI3K-gamma). Preclinical ... help overcome resistance to checkpoint inhibition by ...
Breaking Medicine Technology: